Program Description & Educational Objectives

This activity succinctly reviews the evolving landscape for the treatment of patients with T-cell lymphoma. Topics addressed include a review of current treatment recommendations and an analysis of recent clinical trial data on the efficacy and safety of established and emerging therapies for the treatment of newly diagnosed and relapsed/refractory peripheral T-cell lymphoma (PTCL) and/or cutaneous T-cell lymphoma (CTCL). Considerations for treatment selection in individuals with these diseases are also provided.

Upon completion of this activity, participants should be better able to:

• Demonstrate knowledge of clinical practice recommendations for the management of peripheral and cutaneous T-cell lymphoma (PTCL and CTCL)
• Cite data on the safety and efficacy of novel therapeutics for PTCL and CTCL, including next-generation cytotoxic agents, epigenetic therapy, and targeted compounds
• Select appropriate therapy for patients with PTCL or CTCL across the clinical spectrum, from newly diagnosed to relapsed/refractory disease

Target Audience

This activity has been designed to meet the educational needs of US hematologists and oncologists and other clinicians involved in the management of T-cell lymphoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: November 11, 2011 - November 10, 2012
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Content Director

Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education

Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University College of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

The Purdue University College of Pharmacy designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by Purdue University College of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.